Last viewed: ADVM

Prices are updated after-hours

ADVM Nasdaq

Adverum Biotechnologies, Inc.

ADVM | News | $10.19 -7.36% -7.95% 310K

|

Health Technology

(0.0% 1d) (-26.4% 1m) (1238.0% 1y) (0.0% 2d) (-3.0% 3d) (-3.0% 7d) (81.33% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 2,114,925,859
http://www.adverum.com
Sec Filling | Patents | 114 employees

(US) Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

gene therapies macular treatment hereditary angioedema

add to watch list Paper trade email alert is off

Press-releases

Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsight
Published: 2024-04-22 (Crawled : 22:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M

|

Health Technology

| 0.89% | O: 0.89% H: 0.0% C: 0.0%
OTLK | News P | $8.2 0.0% 240K

|

Health Technology

| 1.36% | O: 1.48% H: 2.8% C: -0.12%
OPT | News | $3.46 2.98% 2.89% 8.2K

|

Health Technology

| -0.59% | O: 3.25% H: 0.0% C: -3.72%
OCUL | News | $4.645 -7.1% -7.64% 3.9M

|

Health Technology

| -1.57% | O: 0.79% H: 0.59% C: -2.34%
KOD | News | $3.37 1.2% 1.19% 340K

|

Health Technology

| -2.63% | O: 0.29% H: 3.79% C: -2.92%
EYPT | News | $16.47 -6.26% -6.68% 1.1M

|

Health Technology

| 3.66% | O: 7.73% H: 2.3% C: -3.78%
CLSD | News P | $1.33 -2.92% -3.01% 200K

|

Health Technology

| -2.84% | O: 1.42% H: 3.5% C: -4.2%
ADVM | News | $10.19 -7.36% -7.95% 310K

|

Health Technology

| -3.0% | O: -0.26% H: 4.95% C: -2.74%
macular growth market

Opthea Appoints John Han, PharmD, as VP Medical Affairs
Published: 2024-04-08 (Crawled : 23:00) - globenewswire.com
REGN | News | $906.55 -0.09% -0.08% 370K

|

Health Technology

| -3.32% | O: 0.31% H: 0.83% C: 0.27%
OPT | News | $3.46 2.98% 2.89% 8.2K

|

Health Technology

| -16.63% | O: -2.73% H: 3.57% C: 3.32%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

|

Health Technology

| 1.61% | O: 0.37% H: 0.38% C: 0.06%
ADVM | News | $10.19 -7.36% -7.95% 310K

|

Health Technology

| -12.56% | O: -0.4% H: 1.52% C: -4.15%
medical

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
Published: 2024-03-18 (Crawled : 20:00) - globenewswire.com
ADVM | News | $10.19 -7.36% -7.95% 310K

|

Health Technology

| 521.47% | O: -15.25% H: 20.0% C: 10.0%
biotechnologies year pipeline financial results

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
ADVM | News | $10.19 -7.36% -7.95% 310K

|

Health Technology

| 458.38% | O: 0.51% H: 3.54% C: 0.0%
conference biotechnologies health care

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-12 (Crawled : 13:00) - globenewswire.com
ADVM | News | $10.19 -7.36% -7.95% 310K

|

Health Technology

| 535.84% | O: 6.36% H: 12.5% C: 8.15%
conference biotechnologies life sciences

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
Published: 2024-02-08 (Crawled : 12:00) - globenewswire.com
ADVM | News | $10.19 -7.36% -7.95% 310K

|

Health Technology

| 291.46% | O: 4.98% H: 0.68% C: -33.22%
biotechnologies positive trial

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
ADVM | News | $10.19 -7.36% -7.95% 310K

|

Health Technology

| 674.65% | O: 20.42% H: 22.22% C: 11.7%
biotechnologies million

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
Published: 2024-02-01 (Crawled : 23:00) - globenewswire.com
ADVM | News | $10.19 -7.36% -7.95% 310K

|

Health Technology

| 824.37% | O: 0.84% H: 25.0% C: 18.33%
biotechnologies review results

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
ADVM | News | $10.19 -7.36% -7.95% 310K

|

Health Technology

| 1070.84% | O: 2.17% H: 16.68% C: 11.47%
biotechnologies

AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032) | DelveInsight `
Published: 2024-01-16 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480

|

Health Technology

| -9.29% | O: -1.83% H: 0.0% C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 16.46% | O: 0.77% H: 0.17% C: -1.65%
SNY | News | $46.66 -2.16% -2.21% 1.7M

|

Health Technology

| -8.92% | O: 0.45% H: 0.06% C: -0.5%
RGNX | $16.05 0.94% 0.93% 350K

|

Health Technology

| 4.13% | O: -0.13% H: 0.0% C: -7.15%
ADVM | News | $10.19 -7.36% -7.95% 310K

|

Health Technology

| 1263.07% | O: -0.69% H: 2.32% C: -0.12%
therapy growth study market

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001415889-24-007715	4	2024-03-12	2023-10-03	Buy	A	85000	85000

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M

|

Consumer Services

BOF | $1.99 70.09% 41.21% 110M

|

ILAG | $0.51 6.03% 40.62% 1.7M

|

LICN | $0.941 68.04% 40.49% 15M

|

AMST | $3.31 65.5% 39.58% 70M

|

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M

|

Technology Services

WIMI | $1.15 58.53% 36.92% 19M

|

Technology Services

AIH | $0.45 12.5% 30.92% 320K

|

Health Services

MULN | News | $3.78 38.46% 27.78% 13M

|

RILY | $29.86 37.48% 27.26% 12M

|

Last 48 Hours Insiders Buying

TGEN P 16000 | $0.685 39.71% 6.6K

|

| 20:01
WABC | $47.86 0.21% 0.21% 140K

|

| 19:30
NWFL | News | $24.6 2.03% 1.99% 9.9K

|

| 17:00
MNSB P 310 | $15.88 -2.93% -3.02% 46K

|

| 15:30
TPL P 3 | $589.01 0.2% -0.04% 53K

|

| 15:01
ISBA P 966 | $18.0001 1.63% 3.1K

|

Finance and Insurance

| 15:01
MEGI | $12.04 0.5% 0.0% 150K

|

| 00:30
CTRN P 29000 | $22.11 -0.54% -0.54% 65K

|

| 22:00
CONN | $3.78 2.16% 2.12% 36K

|

| 21:30
CMTV P 700 | $16.59 17.43% 1K

|

Finance and Insurance

| 18:30
FNB | $13.67 0.29% 0.0% 2.2M

|

| 17:30
RMCF | $3.54 0.28% 7.1K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar